SurgiBot Sunk? TransEnterix Turns To Alternative Robot System After FDA Denial
This article was originally published in The Gray Sheet
Executive Summary
The company plans to reduce headcount and investment focused on its SurgiBot laparoscopic robotic surgery system, recognizing that it does not have the resources to put together a new 510(k) and, at the time, prepare a recently acquired system for FDA submission.